| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000411744 |
| ISSN: | 1665-2681 |
| Autores: | Aldámiz Echevarría, Teresa1 González García, Juan2 Wichmann, Miguel A. Von3 Crespo, Manel4 López Aldeguer, José5 Quereda, Carmen6 Téllez, María J7 Galindo, María J8 Sanz, José9 Santos, Ignacio10 Guardiola, Josep M11 Bellón, José M1 Montes, Marisa2 Berenguer, Juan1 |
| Instituciones: | 1Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Madrid. España 2Universidad Autónoma de Madrid, Hospital Universitario La Paz, Madrid. España 3Hospital Donostia, San Sebastián, Guipúzcoa. España 4Hospital de la Vall d'Hebron, Barcelona. España 5Hospital Universitario La Fe, Valencia. España 6Hospital Universitario Ramón y Cajal, Madrid. España 7Hospital Clínico San Carlos, Madrid. España 8Hospital Clínico Universitario, Valencia. España 9Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid. España 10Hospital Universitario La Princesa, Madrid. España 11Hospital Santa Creu i Sant Pau, Barcelona. España |
| Año: | 2015 |
| Periodo: | Jul-Ago |
| Volumen: | 14 |
| Número: | 4 |
| Paginación: | 464-469 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | We assessed the association of CD4+ T-cell counts and HIV-RNA on sustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coinfected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between 2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results. We studied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reduced odds of SVR included genotype 1 or 4, HCV-RNA > 500,000 IU/mL, advanced liver fibrosis, CDC clinical category C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparison with patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio [95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57) for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclusions. Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However, this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this represents a true association of HIV-RNA on response to PR or a spurious association due to poor adherence to treatment |
| Disciplinas: | Medicina |
| Palabras clave: | Gastroenterología, Hepatitis C, Hepatitis crónica, VIH, Coinfecciones, Interferón pegilado, Ribavirina, Respuesta viral |
| Keyword: | Medicine, Gastroenterology, Hepatitis C, Chronic hepatitis, HIV, Coinfections, Pegylated interferon, Ribavirin, Viral response |
| Texto completo: | Texto completo (Ver PDF) |
